Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

NCT06762769 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Smouldering Myeloma

Interventions

DRUG: Isatuximab
DRUG: Iberdomide
DRUG: Dexamethasone

Sponsor

University College, London

Collaborators

[object Object]
[object Object]